The Copenhagen Insulin and Metformin Therapy Trial (CIMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00657943

Recruitment Status : Completed

First Posted : April 14, 2008

Last Update Posted : February 4, 2014

Sponsor:

Collaborators:

Hvidovre University Hospital

Hillerod Hospital, Denmark

Frederiksberg University Hospital

University Hospital, Gentofte, Copenhagen

Rigshospitalet, Denmark

Bispebjerg Hospital

Herlev Hospital

Zealand University Hospital

Copenhagen Trial Unit, Center for Clinical Intervention Research

Novo Nordisk A/S

Information provided by (Responsible Party):

Lise Tarnow, Steno Diabetes Center Copenhagen

Study Description

Brief Summary:

Type 2 Diabetes Mellitus patients (T2DM) have an increased mortality rate due to macrovascular disease. The primary objective of the study is to evaluate the effect of an 18-month treatment with metformin versus placebo in combination with one of three insulin analogue regimens following a treat-to-target principle. The primary outcome measure is change in wall thickness of the carotic arteries(CIMT)measured by ultrasound. A total of 900 patients with T2DM and HbA1c above 7.5% will be included.

Condition or disease	Intervention/treatment	Phase
Type 2 Diabetes Atherosclerosis Arteriosclerosis	Drug: metformin Drug: insulin detemir Drug: insulin aspart + insulin aspart protamin Drug: Insulin aspart	Phase 4

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	415 participants
Allocation:	Randomized
Intervention Model:	Factorial Assignment
Masking:	Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial
Study Start Date :	April 2008
Actual Primary Completion Date :	December 2012
Actual Study Completion Date :	December 2012

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Type 2 diabetes

Drug Information available for: Metformin Metformin hydrochloride Insulin Insulin human

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1M Metformin + Levemir x1	Drug: metformin metformin tablets 2 g x 2 Other Name: glucophage Drug: insulin detemir insulin as requested Other Name: Levemir
Placebo Comparator: 1P Placebo + Levemir x1	Drug: insulin detemir insulin as requested Other Name: Levemir
Experimental: 2M metformin + NovoMix	Drug: metformin metformin tablets 2 g x 2 Other Name: glucophage Drug: insulin aspart + insulin aspart protamin insulin as requested Other Name: novomix
Placebo Comparator: 2P Placebo + NovoMix	Drug: insulin aspart + insulin aspart protamin insulin as requested Other Name: novomix
Experimental: 3M Metformin + 4x therapy	Drug: metformin metformin tablets 2 g x 2 Other Name: glucophage Drug: insulin detemir insulin as requested Other Name: Levemir Drug: Insulin aspart insulin as requested Other Name: NovoRapid
Placebo Comparator: 3P Placebo + 4x therapy	Drug: insulin detemir insulin as requested Other Name: Levemir Drug: Insulin aspart insulin as requested Other Name: NovoRapid

Outcome Measures

Primary Outcome Measures :

Carotid intima media thickness [ Time Frame: 18 months ]

Secondary Outcome Measures :

adverse events [ Time Frame: 18 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	30 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males and females over 30 years of age
Type 2 diabetes
Body mass index (BMI): 25.0-39.9 kg/m2
HbA1c above 7.5 %
Antidiabetic tablet-treatment during 1 year minimum AND / OR
Insulin treatment during a minimum of 3 months
Negative pregnancy test
Signed, informed consent

Exclusion Criteria:

MI, coronary revascularization, TCI,or apoplexy within the last 3 months
TCI with verified stenosis of above 70%
Heart failure (NYHA class III or IV)
Former cancer patient, unless disease-free period of more than 5 years
estimated creatinine clearance < 60 ml/min Liver disease
Alcohol abuse
Drug abuse
Retinopathy with on-going laser treatment at start of study
Other acute or chronic serious disease leading to hypoxia
Pregnant or breastfeeding women
Women of child-bearing potential, not using contraceptives
Allergy to medication used in the study
Incapable of understanding the nature of the informed consent

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00657943

Locations

Layout table for location information

Denmark
Rigshospitalet
Copenhagen, Denmark, 2100
Bispebjerg Hospital
Copenhagen, Denmark, 2400
Frederiksberg Hospital
Frederiksberg, Denmark, 2000
Gentofte Sygehus
Gentofte, Denmark, 2820
Steno Diabetes Center
Gentofte, Denmark, 2820
Herlev Hospital
Herlev, Denmark, 2830
Hillerod Sygehus
Hillerod, Denmark, 3400
Hvidovre Hospital
Hvidovre, Denmark, 2650
Køge Sygehus
Koge, Denmark, 4600

Sponsors and Collaborators

Steno Diabetes Center Copenhagen

Hvidovre University Hospital

Hillerod Hospital, Denmark

Frederiksberg University Hospital

University Hospital, Gentofte, Copenhagen

Rigshospitalet, Denmark

Bispebjerg Hospital

Herlev Hospital

Zealand University Hospital

Copenhagen Trial Unit, Center for Clinical Intervention Research

Novo Nordisk A/S

Investigators

Layout table for investigator information

Principal Investigator:	Thomas Almdal, MD DMSc	Hvidovre University Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L, Gade-Rasmussen B, Sneppen SB, Gluud C, Hemmingsen B, Jensen T, Krarup T, Madsbad S, Mathiesen ER, Perrild H, Tarnow L, Thorsteinsson B, Vestergaard H, Lund SS, Eiken P. The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporos Int. 2018 Nov;29(11):2517-2526. doi: 10.1007/s00198-018-4637-z. Epub 2018 Jul 19.

Lundby-Christensen L, Vaag A, Tarnow L, Almdal TP, Lund SS, Wetterslev J, Gluud C, Boesgaard TW, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open. 2016 Feb 25;6(2):e008377. doi: 10.1136/bmjopen-2015-008377.

Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open. 2016 Feb 25;6(2):e008376. doi: 10.1136/bmjopen-2015-008376.

Layout table for additonal information

Responsible Party:	Lise Tarnow, professor, Steno Diabetes Center Copenhagen
ClinicalTrials.gov Identifier:	NCT00657943 History of Changes
Other Study ID Numbers:	EudraCT 2007-006665-33
First Posted:	April 14, 2008 Key Record Dates
Last Update Posted:	February 4, 2014
Last Verified:	February 2014

Keywords provided by Lise Tarnow, Steno Diabetes Center Copenhagen:


carotid intima media	thickness insulin metformin

Additional relevant MeSH terms:

Layout table for MeSH terms

Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Insulin Insulin, Globin Zinc Metformin Insulin Aspart	Insulin, Long-Acting Insulin degludec, insulin aspart drug combination Insulin Detemir Protamines Hypoglycemic Agents Physiological Effects of Drugs Heparin Antagonists Molecular Mechanisms of Pharmacological Action Coagulants

To Top